

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>La Barge Joseph</u>  (Last) (First) (Middle) C/O SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300  (Street) PHILADELPHIA PA 19104  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Spark Therapeutics, Inc. [ ONCE ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Legal Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>03/25/2019</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/25/2019		M		41,755	A	\$68.45	63,237	D	
Common Stock	03/25/2019		F		31,389	D	\$113.42	31,848	D	
Common Stock	03/25/2019		M		33,748	A	\$40.44	65,596	D	
Common Stock	03/25/2019		F		21,260	D	\$113.38	44,336	D	
Common Stock	03/25/2019		M		12,500	A	\$56.17	56,836	D	
Common Stock	03/25/2019		F		8,873	D	\$113.36	47,963	D	
Common Stock	03/25/2019		M		7,000	A	\$50.55	54,963	D	
Common Stock	03/25/2019		F		4,770	D	\$113.36	50,193	D	
Common Stock								200	I	Held by Reporting Person's immediate family members

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (right to buy)	\$68.45	03/25/2019		M			41,755	(1)	03/15/2025	Common Stock	41,755	\$0.00	0	D	
Stock Option (right to buy)	\$40.44	03/25/2019		M			33,748	(2)	01/04/2026	Common Stock	33,748	\$0.00	11,250	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$56.17	03/25/2019		M			12,500	(3)	01/17/2027	Common Stock	12,500	\$0.00	12,500	D	
Stock Option (right to buy)	\$50.55	03/25/2019		M			7,000	(4)	01/17/2028	Common Stock	7,000	\$0.00	21,000	D	

**Explanation of Responses:**

1. 25% vested March 16, 2016 and the remainder vested in equal quarterly installments over the following three years.
2. 25% vested January 5, 2017 and the remainder vests in equal quarterly installments over the following three years.
3. 25% vested January 18, 2018 and the remainder vests in equal annual installments over the following three years.
4. 25% vested January 18, 2019 and the remainder vests in equal annual installments over the following three years.

**Remarks:**

/s/ Joseph W. La Barge                      03/27/2019

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.